checkAd

     221  0 Kommentare uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy - Seite 3

    uniQure Contacts:

    FOR INVESTORS:       FOR MEDIA:
             
    Maria E. Cantor   Chiara Russo   Tom Malone
    Direct: 339-970-7536   Direct: 617-306-9137   Direct: 339-970-7558
    Mobile: 617-680-9452   Mobile: 617-306-9137   Mobile:339-223-8541
    m.cantor@uniQure.com   c.russo@uniQure.com   t.malone@uniQure.com

    Lesen Sie auch



    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy - Seite 3 Clinical trial initiation expected in the fourth quarter of 2023LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with …